The Medical Letter ® on Drugs and Therapeutics Volume 59 ISSUE ISSUE No 1433 1514 Volume 56 February 13, 2017 DRUGS FOR MIGRAINE Treatment p 27 Prevention p 30 Comparison Charts: Triptans and Drugs for Migraine Prevention online only Important Copyright Message FORWARDING OR COPYING IS A VIOLATION OF U.S AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter, Inc publications are protected by U.S and international copyright laws Forwarding, copying or any distribution of this material is prohibited Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited By accessing and reading the attached content I agree to comply with U.S and international copyright laws and these terms and conditions of The Medical Letter, Inc For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769 Published by The Medical Letter, Inc • A Nonprofit Organization The Medical Letter publications are protected by US and international copyright laws Forwarding, copying or any other distribution of this material is strictly prohibited For further information call: 800-211-2769 The Medical Letter ® on Drugs and Therapeutics Volume 59 February 13, 2017 Take CME Exams ISSUE ISSUE No 1433 1514 Volume 56 ▶ DRUGS FOR MIGRAINE Treatment p 27 Prevention p 30 Comparison Charts: Triptans and Drugs for Migraine Prevention online only Treatment of Migraine Recommendations for Treatment and Prevention of Migraine Treatment An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting A triptan is the drug of choice for treatment of moderate to severe migraine.1,2 Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates ▶ A nonopioid analgesic may be effective for mild to moderate ANALGESICS – Aspirin and acetaminophen, used alone or together in combination with caffeine (Excedrin Migraine, and others), and nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen sodium (Aleve, and others) and ibuprofen (Advil, Motrin, and generics) are effective in relieving mild to moderate migraine pain.3-5 The NSAID diclofenac is FDA-approved as a powder for oral solution (Cambia) for treatment of migraine; it has a rapid onset of action (about 15 minutes).6 Some patients may respond better to one NSAID than to another ▶ Products that combine butalbital and caffeine with aspirin (Fiorinal, and others) or acetaminophen (Fioricet, and others) are used for treatment of migraine despite evidence that butalbital is not effective in relieving migraine pain Their frequent use can lead to tolerance, addiction, and medication overuse headache Oral combinations of aspirin or acetaminophen with an opioid can be effective for relief of migraine pain, but they cause the usual opioid adverse effects (e.g., nausea, drowsiness, and constipation), and regular use can lead to dependence and addiction Pregnancy – Occasional use of acetaminophen for treatment of mild to moderate migraine during pregnancy is generally considered safe TRIPTANS – The short-acting oral serotonin (5-HT1B/1D) receptor agonists (triptans) sumatriptan (Imitrex, and others), almotriptan (Axert, and generics), eletriptan migraine ▶ A triptan is the drug of choice for moderate to severe migraine ▶ The short-acting oral triptans sumatriptan, almotriptan, ▶ ▶ ▶ eletriptan, rizatriptan, and zolmitriptan are similar in efficacy and speed of onset Intranasal triptan formulations have a faster onset of action than oral triptans Subcutaneous sumatriptan is the fastest-acting and most effective triptan formulation Patients who not respond to one triptan may respond to another Use of opioids and butalbital for migraine treatment is discouraged Prevention ▶ Topiramate, valproate, and the beta blockers propranolol, timolol, and metoprolol are effective for prevention of migraine (Relpax), rizatriptan (Maxalt, and generics), and zolmitriptan (Zomig, and generics) are similar in efficacy.7 Onset of pain relief generally occurs 3060 minutes after administration The longer-acting oral triptans naratriptan (Amerge, and generics) and frovatriptan (Frova, and generics) have a slower onset of action and lower initial response rate than other triptans, but they are better tolerated.8 Patients with migraine who have nausea or vomiting may not be able to take an oral triptan An oral fixed-dose combination of sumatriptan and naproxen (Treximet) is more effective in relieving moderate or severe migraine pain than either of its components alone.9 Intranasal triptan formulations have a more rapid onset of action than oral tablets, but their efficacy is partially dependent on GI absorption of the portion of the dose that is swallowed Use of sumatriptan nasal powder (Onzetra Xsail) results in a faster rise in sumatriptan Comparison Chart of Triptans (online only) www.medicalletter.org/downloads/triptans.pdf 27 Published by The Medical Letter, Inc • A Nonprofit Organization The Medical Letter Vol 59 (1514) ® Table Triptans Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan tablets nasal spray and powder SC injection Zolmitriptan tablets nasal spray Onset of action Elimination half-life 30-60 30-60 ~2 hrs 1-3 hrs 30-60 3-4 hrs ~4 hrs ~25 hrs ~6 hrs 2-3 hrs ~2 hrs 30-60 10-15 ~10 30-60 10-15 2-3 hrs plasma concentrations and higher peak concentrations than use of a similar dose of sumatriptan nasal spray, suggesting that a larger portion of the dose is absorbed intranasally with the powder.10 Subcutaneously administered sumatriptan relieves pain faster (in about 10 minutes) and more effectively than other triptan formulations, but it causes more adverse effects Recurrence – In patients with moderate to severe migraine, the rate of recurrence within 24 hours after treatment with a triptan is generally 20-40% Early treatment of an attack reduces recurrence rates Recurrences may respond to a second dose of the triptan Adverse Effects – Tingling, flushing, dizziness, drowsiness, fatigue, and a feeling of heaviness, tightness, or pressure in the chest can occur with all triptans, but most commonly with SC sumatriptan A burning sensation at the injection site is also common with SC sumatriptan Intranasal formulations of sumatriptan and zolmitriptan can have an unpleasant taste CNS symptoms such as somnolence and asthenia following triptan therapy may be part of the migraine attack, unmasked by the successful treatment of pain, rather than adverse effects of the drugs Sumatriptan is contraindicated for use in patients with severe hepatic impairment Naratriptan is contraindicated in patients with severe renal or hepatic impairment Angina, myocardial infarction, cardiac arrhythmia, stroke, seizure, and death have occurred rarely with triptans.11 All triptans are contraindicated for use in patients with ischemic or vasospastic coronary artery disease, Wolff-Parkinson-White syndrome, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, or a history of stroke, transient ischemic attack, hemiplegic migraine, or migraine with brainstem aura Triptans should be used with caution in patients with other significant risk factors for vascular disease, particularly diabetes 28 February 13, 2017 Drug Interactions – The labels of all triptans state that a triptan should not be taken within 24 hours of another triptan or an ergot because vasoconstriction could be additive MAO inhibitors increase serum concentrations of rizatriptan, sumatriptan, and zolmitriptan; they should not be used within weeks of each other Propranolol increases serum concentrations of eletriptan, frovatriptan, rizatriptan, and zolmitriptan Cimetidine increases serum concentrations of zolmitriptan Inhibitors of CYP3A4 can increase serum concentrations of almotriptan and eletriptan.12 Cases of serotonin syndrome have been reported with concurrent use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), but data from large observational databases suggest that the risk is low.13,14 Pregnancy and Lactation – Based on available evidence, use of sumatriptan, or possibly rizatriptan, eletriptan, or zolmitriptan during pregnancy does not appear to be associated with an increased risk of birth defects.15,16 Levels of sumatriptan and eletriptan in breast milk are low and these drugs would not be expected to cause adverse effects in most breastfed infants17; avoiding breastfeeding for 8-12 hours after taking a short-acting triptan would reduce the infant's risk of exposure to the drug ERGOTS – A fixed-dose combination of ergotamine tartrate, a nonspecific serotonin agonist and vasoconstrictor, and caffeine is available as tablets (Cafergot) and suppositories (Migergot) for treatment of moderate to severe migraine The combination is less effective than a triptan for acute treatment of migraine.18 Dihydroergotamine, which can be administered subcutaneously, intramuscularly, intravenously (D.H.E., and generics), or intranasally (Migranal), is effective for acute treatment of migraine Dihydroergotamine nasal spray relieves migraine after hours in about 50% of patients, with a 15% incidence of recurrence within 24 hours It can be effective in some patients who not respond to triptans Adverse Effects – Dihydroergotamine is a weaker arterial vasoconstrictor than ergotamine and causes fewer serious adverse effects Nausea and vomiting are fairly common with ergotamine, but pretreatment with or concurrent use of an antiemetic such as metoclopramide (Reglan, and generics) can reduce GI effects Serious adverse effects, such as vascular (including coronary) occlusion and gangrene, are rare and are usually associated with overdosage (>6 mg in 24 hours or >10 mg per week) Hepatic impairment The Medical Letter Vol 59 (1514) ® February 13, 2017 Table Some Drugs for Treatment of Migraine Drug Triptans Almotriptan3 – generic Axert (Janssen) Eletriptan – Relpax (Pfizer) Frovatriptan – generic Frova (Endo) Naratriptan – generic Amerge (GSK) Rizatriptan4 – generic Maxalt (Merck) Maxalt-MLT Sumatriptan – generic Imitrex (GSK) Formulations Usual Adult Dosage1 Cost2 6.25, 12.5 mg tabs 6.25 or 12.5 mg PO; can be repeated after hrs (max 25 mg/d) 20 or 40 mg PO; can be repeated after hrs (max 80 mg/d) 2.5 mg PO; can be repeated after hrs (max 7.5 mg/d) 2.5 mg PO; can be repeated after hrs (max mg/d) or 10 mg PO; can be repeated after hrs (max 30 mg/d)5,6 $33.00 42.70 52.00 20, 40 mg tabs 2.5 mg tabs 1, 2.5 mg tabs 5, 10 mg tabs 5, 10 mg orally disintegrating tabs 5, 10 mg tabs 5, 10 mg orally disintegrating tabs 25, 50, 100 mg tabs mg/0.5 mL, vials; 4, mg/0.5 mL auto-injector pen and refill cartridge7 5, 20 mg/0.1 mL nasal spray Onzetra Xsail (Avanir) 11 mg nasal powder capsules Sumavel DosePro (Endo) mg/0.5 mL needle-free delivery system mg/0.5 mL auto-injector Zembrace SymTouch (Promius) Zolmitriptan – generic Zomig (Impax) Zomig-ZMT Zomig nasal spray3 Triptan/NSAID Combination Sumatriptan/naproxen3 – Treximet (Pernix) Ergots Dihydroergotamine mesylate – generic D.H.E 45 (Valeant) Migranal nasal spray (Valeant) Ergotamine/caffeine – generic Cafergot (Sandoz) Migergot (Horizon) 50 or 100 mg PO; can be repeated after hrs (max 200 mg/d) mg SC; can be repeated after hr (max 12 mg/d) 2.5, mg tabs 2.5, mg orally disintegrating tabs 2.5, mg tabs 2.5, mg orally disintegrating tabs 2.5, mg/0.1 mL nasal spray 5, 10, or 20 mg intranasally; can be repeated after hrs (max 40 mg/d) 22 mg intranasally; can be repeated after hrs (max 44 mg/d) mg SC; can be repeated after hr (max 12 mg/d) mg SC; can be repeated after hr (max 12 mg/d) 2.5 or mg PO; can be repeated after hrs (max 10 mg/d)8 2.5 or mg intranasally; can be repeated after hrs (max 10 mg/d) 10/60, 85/500 mg tabs 85/500 mg PO; can be repeated after hrs (max 170/1000 mg/d)9 mg/mL ampules mg IM or SC; can be repeated at hr intervals (max mg/d, mg/wk) spray (0.5 mg) into each nostril, repeated 15 later (2 mg/dose; max mg/d) tabs PO at attack onset, then tab q30 PRN (max tabs/attack) supp at attack onset, repeat in hr if needed (max supp/attack) mg/mL nasal spray 1/100 mg tabs 2/100 mg rectal suppository 53.60 73.60 11.00 56.60 1.60 3.20 36.60 36.60 2.00 60.40 45.10 176.10 49.20 75.40 65.00 169.20 149.80 26.20 27.70 89.40 89.40 61.50 81.00 124.80 1176.80 421.40 11.10 12.40 63.90 Dosage may need to be adjusted for renal or hepatic impairment or for drug interactions Approximate WAC for one dose at the lowest usual dosage WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price Source: AnalySource® Monthly January 5, 2017 Reprinted with permission by First Databank, Inc All rights reserved ©2017 www.fdbhealth.com/policies/drug-pricing-policy Also approved for use in patients 12-17 years old Also approved for use in patients 6-17 years old Dose for pediatric patients is mg (